跳至主要内容
临床试验/NCT01107327
NCT01107327已完成不适用

FDG PET in Cancer Associated Venothromboembolism

University of Utah1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
26
试验地点
1
主要终点
Accuracy of FDG PET/CT scanning to diagnose presence, extent, and acuity of Ventothromboembolism diagnosis.

研究概览

简要总结

Venothromboembolic disease (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is a severe health problem, effecting 1.5/1000 per year in the general population. In patients over 60 years of age, the incidence is 1/100 per year. Of the two million Americans per year who will develop VTE, one third will develop pulmonary embolism (PE). VTE is usually diagnosed by Doppler ultrasound or contrast venography when present in the extremities, VQ scan or pulmonary angiography when PE is present. However, there are many instances when the diagnosis of VTE by conventional modalities is limited. These include obesity, recent trauma or surgery, the presence of a mass, the presence of clot around central lines, and clot occurring in the abdomen and pelvis. Furthermore, the differentiation between new and old clot has evaded all diagnostic imaging modalities, and no existing modality allows for an accurate delineation of all sites of thrombus within the body. New approaches to the diagnostic imaging of VTE in complicated cases are needed. The first hypothesis of this project is that FDG PET/CT can be used to accurately diagnose the presence and extent of acute VTE, and that it will distinguish new clot from old.

Approximately 20-25% of all new cases of venous thromboembolism occur in known cancer patients. The risk of VTE is 4-6 fold greater in patients with cancer as those without (8-12% vs. 2%, respectively, lifetime risk). In many cases, the development of VTE occurs as the first clinical sign of the cancer, even before it is diagnosed. Among patients presenting with acute VTE have no obvious cause (defined as "idiopathic" or "unprovoked", as opposed to "secondary" VTE), the literature reports that up to 20% (range of reported incidence 7-20%) may ultimately prove to have cancer, depending on the series and whether the thrombosis is unifocal or multifocal. Despite the substantial prevalence of occult cancer in patients presenting with idiopathic VTE, there are no current recommendations that these patients be screened for the presence of cancer. The second hypothesis of the project is that FDG PET/CT can accurately be used to screen for the presence of cancer in patients with unprovoked (idiopathic) acute VTE.

Objectives:

There are two specific objectives to test the hypotheses associated with this project:

  1. To establish the sensitivity of FDG PET/CT in the diagnosis of acute VTE.
  2. To perform a pilot project to aid in the design of a larger trial to define the incidence of occult cancer in patients rigorously selected for idiopathic (unprovoked) VTE, and to investigate the value of FDG PET in the early detection of occult cancer in this population.

详细描述

Study AIM #1 To establish the sensitivity of FDG PET/CT in the diagnosis of acute VTE.

Rationale: We believe that FDG PET/CT can be used to accurately diagnose the presence, extent, and acuity of VTE. It is unrealistic to assume that FDG-PET could or should become the primary imaging modality for evaluating VTE. The cost, compared to Doppler ultrasound, would be prohibitive, and would involve unnecessary radiation of the patient. We intend to establish the value of FDG PET, instead, as an alternative modality for the diagnosis of VTE. Clinical situations where this might prove useful include: 1) the presence of old clot, when the distinction between new and old may be important; 2) evaluation of abdominal, pelvic and thoracic thrombus, where Doppler is difficult-to-impossible because of patient obesity; 3) Complicated anatomy due to the presence of tumor or post-therapeutic changes.

The sensitivity of FDG PET/CT will be established in patients with acute VTE. The accuracy with which sites of abnormal FDG uptake can be related, spatially, to vascular structures will be critical to the success of this study. There is little doubt that this can better be accomplished with PET/CT than with PET alone. PET/CT will be used for all of these studies. Patients with documented acute VTE, will be enrolled. To determine the utility of FDG PET/CT in distinguishing acute from subacute or chronic clot, and to establish the extent of acute clot, the initial whole body PET/CT scan must be performed within 2 weeks of onset of symptoms of DVT, and subsequent limited region PET/CT scans will be performed at 2-3 weeks and at 6 weeks following the initial PET/CT scan. Whenever possible, subjects will be recruited who have unprovoked VTE because the potential benefit to the patient for participating in this study will be greatest for these patients are at a higher risk for harboring an underlying occult malignancy. However, patients with both provoked and unprovoked VTE will be eligible for enrollment under this specific aim.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria will include documented acute DVT (+/-PE) by Doppler ultrasound or contrast venography.
  • Subjects will be eligible either with provoked or unprovoked DVT.
  • To meet the inclusion criteria, patients must be enrolled and the initial PET/CT scan performed within 2 weeks of initial onset of symptoms of VTE.

排除标准

  • Subjects less than 18 years of age,
  • Those who are unable to understand and provide signature informed consent
  • Pregnant subjects. Any female of childbearing age who has a uterus and functional ovaries will undergo a serum pregnancy test prior to inclusion.
  • Subjects with calf-only blood clot will be excluded, due to the fact that these cases are often complicated by venous stasis disease, post-phlebitic syndrome, and the presence of both acute and chronic clot, which may compromise interpretation.

结局指标

主要结局

Accuracy of FDG PET/CT scanning to diagnose presence, extent, and acuity of Ventothromboembolism diagnosis.

时间窗: April 2012

We believe that FDG PET/CT can be used to accurately diagnose the presence, extent, and acuity of VTE. We intend to establish the value of FDG PET, instead, as an alternative modality for the diagnosis of VTE. Clinical situations where this might prove useful include: 1) the presence of old clot, when the distinction between new and old may be important; 2) evaluation of abdominal, pelvic and thoracic thrombus, where Doppler is difficult-to-impossible because of patient obesity; 3) Complicated anatomy due to the presence of tumor or post-therapeutic changes.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Fluorodeoxyglucose (FDG)-Positron Emission... | 临床试验